Nocturnal Enuresis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Nocturnal Enuresis Epidemiology Forecast Report Coverage

Expert Market Research's “Nocturnal Enuresis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of nocturnal enuresis. It projects the future incidence and prevalence rates of nocturnal enuresis cases across various populations. The study covers age, gender, and type as major determinants of the nocturnal enuresis population. The report highlights patterns in the prevalence of nocturnal enuresis over time and projects future trends based on multiple variables.

Nocturnal Enuresis Understanding: Disease Overview

Nocturnal enuresis (NE), commonly referred to as nighttime bedwetting, is a frequent pediatric condition characterized by involuntary urination during sleep beyond the age of expected bladder control. It is broadly classified into monosymptomatic nocturnal enuresis (MNE), which occurs without other urinary symptoms, and non-monosymptomatic nocturnal enuresis (NMNE), associated with lower urinary tract issues. While nocturnal enuresis often resolves with age, it can cause significant psychosocial stress for children and families. The condition arises from a complex interplay of delayed bladder maturation, genetics, sleep patterns, and urine production.

Nocturnal Enuresis Epidemiology Perspective

The nocturnal enuresis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the nocturnal enuresis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for nocturnal enuresis and its trends. The nocturnal enuresis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• A 2025 systematic review and meta-analysis reported an overall pooled prevalence of approximately 7.2% among children and adolescents across the evaluated studies.
• The prevalence of nocturnal enuresis shows a marked age-related decline, affecting around 25% of children at age 4, 15% at age 5, and about 4% by age 8. By adolescence, the rates drop to low single digits, with primary nocturnal enuresis (PNE) most common in younger children and gradually decreasing each year.
• Studies from 2020 to 2025 consistently highlight a male predominance, with boys experiencing nocturnal enuresis at roughly 1.5 to 2 times the rate of girls. Multiple analyses confirm male sex as a significant risk factor.

Read more about this report - Request a Free Sample

Country-wise Nocturnal Enuresis Epidemiology Segment

The nocturnal enuresis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In European countries, particularly Italy, the epidemiology of nocturnal enuresis (NE) varies. Yet consistent trends are observed in both prevalence and subtype distribution. A large survey of more than 130,000 children reported an overall NE prevalence of 7.1%, with monosymptomatic NE (MNE) comprising only 25%, while the majority (75%) were non-monosymptomatic NE (NMNE). Notably, a strong family history was documented in 31.2% of cases, emphasizing the genetic predisposition. These findings highlight the importance of country-specific data to inform early diagnosis and targeted management strategies.

Nocturnal Enuresis: Treatment Overview

The management of nocturnal enuresis involves a combination of behavioral strategies, pharmacological interventions, and supportive care. First-line approaches include education, reassurance, and lifestyle modifications, such as limiting evening fluid intake and bladder training. Enuresis alarms, which condition arousal responses, are widely recognized as effective. Pharmacological options, particularly desmopressin, are used when behavioral measures are insufficient or rapid control is desired. Anticholinergics or combination therapy may be considered for resistant cases. Multidisciplinary care ensures optimal outcomes, addressing both clinical symptoms and the emotional impact on affected children and their families.

Key Questions Answered

• What are the key findings of nocturnal enuresis epidemiology in the 8 major markets?
• What will be the total number of patients with nocturnal enuresis across the 8 major markets during the forecast period?
• What was the country-wise nocturnal enuresis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of nocturnal enuresis during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of nocturnal enuresis during the forecast period of 2026-2035?
• What are the currently available treatments for nocturnal enuresis?
• What are the disease risks, signs, symptoms, and unmet needs of nocturnal enuresis?

Scope of the Nocturnal Enuresis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of nocturnal enuresis based on several factors.
• Nocturnal Enuresis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The nocturnal enuresis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Urinary Incontinence Market Report

Urinary Incontinence Drugs Market Report